Strados Labs offers innovative respiratory monitoring solutions, including the FDA-cleared RESP® Biosensor, a wearable device designed to continuously capture and analyze lung sounds such as coughing and wheezing. This technology facilitates remote patient monitoring by providing real-time data that can enhance treatment plans and research studies. The device is user-friendly; patients simply adhere it to their chest, allowing for uninterrupted monitoring throughout the day and night. Data collected is transmitted via Bluetooth to a mobile app and securely stored in the cloud for tracking and analysis.

Founded with a mission to improve lung health monitoring from hospital to home, Strados Labs focuses on chronic respiratory conditions like asthma, chronic cough, COPD, and idiopathic pulmonary fibrosis (IPF). The company emphasizes privacy and security in its design, incorporating advanced encryption technology. Strados Labs has achieved significant milestones, including over 600,000 validated cough captures across four continents in 35 languages. Their commitment to innovation is reflected in their development of tools that provide objective insights for both healthcare providers and clinical trials.